Sol-Gel Technologies (SLGL) Change in Account Payables (2018 - 2019)
Sol-Gel Technologies (SLGL) reported Change in Account Payables of $5.0 million for Q3 2019, up 23.68% quarter-over-quarter from $4.1 million in Q2 2019.
Sol-Gel Technologies (SLGL) Change in Account Payables (2018 - 2019) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Change in Account Payables data on file, last reported at $5.0 million in Q3 2019.
- Change in Account Payables for Q3 2019 came in at $5.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $5.0 million (changed N/A YoY), and the FY2018 annual result was $2.0 million, changed N/A from the prior year.
- Change in Account Payables rose to $5.0 million in Q3 2019 per SLGL's latest filing, from $4.1 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $5.0 million in Q3 2019 and troughed at $2.0 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 5.03 Mn |
| Sep 30, 2019 | 5.03 Mn |
| Jun 30, 2019 | 4.06 Mn |
| Jun 30, 2019 | 4.06 Mn |
| Mar 31, 2019 | 2.90 Mn |
| Mar 31, 2019 | 2.90 Mn |
| Dec 31, 2018 | 1.97 Mn |
| Dec 31, 2018 | 1.97 Mn |